621 related articles for article (PubMed ID: 24367037)
1. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
Maillart E; Louapre C; Lubetzki C; Papeix C
Mult Scler; 2014 Apr; 20(4):505-9. PubMed ID: 24367037
[TBL] [Abstract][Full Text] [Related]
2. Comment on 'Fingolimod to treat severe MS after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?' Maillart et al.
Tur C; Montalban X
Mult Scler; 2014 Apr; 20(4):510-1. PubMed ID: 24468818
[No Abstract] [Full Text] [Related]
3. Severe relapses under fingolimod treatment prescribed after natalizumab.
Centonze D; Rossi S; Rinaldi F; Gallo P
Neurology; 2012 Nov; 79(19):2004-5. PubMed ID: 23035063
[No Abstract] [Full Text] [Related]
4. Switching from natalizumab to fingolimod: an observational study.
Sempere AP; Martín-Medina P; Berenguer-Ruiz L; Pérez-Carmona N; Sanchez-Perez R; Polache-Vengud J; Feliu-Rey E
Acta Neurol Scand; 2013 Aug; 128(2):e6-e10. PubMed ID: 23336398
[TBL] [Abstract][Full Text] [Related]
5. Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?
Wipfler P; Harrer A; Pilz G; Oppermann K; Afazel S; Haschke-Becher E; Sellner J; Trinka E; Kraus J
Acta Neurol Scand; 2014 Mar; 129(3):e12-5. PubMed ID: 24032536
[TBL] [Abstract][Full Text] [Related]
6. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
Gajofatto A; Bianchi MR; Deotto L; Benedetti MD
Eur Neurol; 2014; 72(3-4):173-80. PubMed ID: 25226868
[TBL] [Abstract][Full Text] [Related]
7. Fingolimod and multiple sclerosis: four cautionary tales.
Bourdette D; Gilden D
Neurology; 2012 Nov; 79(19):1942-3. PubMed ID: 23035058
[No Abstract] [Full Text] [Related]
8. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
Campbell JD; McQueen RB; Miravalle A; Corboy JR; Vollmer TL; Nair K
Am J Manag Care; 2013 Apr; 19(4):278-85. PubMed ID: 23725360
[TBL] [Abstract][Full Text] [Related]
9. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
Soilu-Hänninen M; Päivärinta M; Sonninen P; Parkkola R; Vuorinen T; Erälinna JP
Duodecim; 2013; 129(7):765-70. PubMed ID: 23720945
[TBL] [Abstract][Full Text] [Related]
10. [[Natalizumab therapy, 2013].
Karácsony M; Bencsik K; Vécsei L
Ideggyogy Sz; 2014 Jul; 67(7-8):220-8. PubMed ID: 25509362
[TBL] [Abstract][Full Text] [Related]
11. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
12. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
Sørensen PS
J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
[TBL] [Abstract][Full Text] [Related]
13. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
Bartt RE
Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
[TBL] [Abstract][Full Text] [Related]
14. Cost-minimization analysis of fingolimod compared with natalizumab for the treatment of relapsing-remitting multiple sclerosis in Sweden.
Bergvall N; Tambour M; Henriksson F; Fredrikson S
J Med Econ; 2013; 16(3):349-57. PubMed ID: 23211038
[TBL] [Abstract][Full Text] [Related]
15. Cost minimisation analysis of fingolimod vs natalizumab as a second line of treatment for relapsing-remitting multiple sclerosis.
Crespo C; Izquierdo G; García-Ruiz A; Granell M; Brosa M
Neurologia; 2014 May; 29(4):210-7. PubMed ID: 24161412
[TBL] [Abstract][Full Text] [Related]
16. Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation.
Berger B; Baumgartner A; Rauer S; Mader I; Luetzen N; Farenkopf U; Stich O
J Neuroimmunol; 2015 May; 282():118-22. PubMed ID: 25903738
[TBL] [Abstract][Full Text] [Related]
17. [Dilemma of further therapeutic step in remitting-relapsing multiple sclerosis in case of ineffectiveness of first-line treatment: fingolimod or natalizumab?].
Gábor L
Ideggyogy Sz; 2014 Mar; 67(3-4):141. PubMed ID: 26118259
[No Abstract] [Full Text] [Related]
18. Early onset of natalizumab-related progressive multifocal leukoencephalopathy.
Damasceno A; von Glehn F; Martinez AR; Longhini AL; Deus-Silva L; Brandão CO; Santos LM; Damasceno BP
Mult Scler; 2011 Nov; 17(11):1397-8. PubMed ID: 21900356
[No Abstract] [Full Text] [Related]
19. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H;
Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031
[TBL] [Abstract][Full Text] [Related]
20. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.
Baldi E; Guareschi A; Vitetta F; Senesi C; Curti E; Montepietra S; Simone AM; Immovilli P; Caniatti L; Tola MR; Pesci I; Montanari E; Sola P; Granella F; Motti L; Ferraro D
Curr Med Res Opin; 2014 Sep; 30(9):1849-55. PubMed ID: 24831186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
